School of Medicine

Showing 1-10 of 10 Results

  • Jason D. Merker, MD, PhD

    Jason D. Merker, MD, PhD

    Assistant Professor of Pathology at the Stanford University Medical Center

    Bio Dr. Merker is a clinical laboratory-based physician who specializes in genetic disease testing for both heritable disease and cancer. He is board-certified in Molecular Genetic Pathology, Clinical Pathology, and Clinical Cytogenetics. Dr. Merker is Co-Director of the Stanford Medicine Clinical Genomics Service, a laboratory section within the Stanford Anatomic Pathology & Clinical Laboratories that uses genomic sequencing and other advanced methods to evaluate the cause of disease in patients with unexplained heritable disease. He also directs an active research group that focuses on two areas: 1) development of improved experimental and computational approaches related to the use of genomic sequencing and other “omics” assays for clinical care, and 2) identification and characterization of acquired and heritable genetic variants that are important for the development of hematologic disorders and other malignancies.

  • Sara Michie

    Sara Michie

    Professor of Pathology (Research)

    Current Research and Scholarly Interests Lymphocyte/endothelial cell adhesion mechanisms involved in lymphocyte migration to sites of inflammation; regulation of expression of endothelial cell adhesion molecules.

  • Michelle Monje

    Michelle Monje

    Assistant Professor of Neurology and, by courtesy, of Neurosurgery, of Pediatrics and of Pathology

    Current Research and Scholarly Interests The Monje Lab studies the molecular and cellular mechanisms of postnatal neurodevelopment. This includes microenvironmental influences on neural precursor cell fate choice in normal neurodevelopment and in disease states.

  • Stephen B. Montgomery

    Stephen B. Montgomery

    Assistant Professor of Pathology, Genetics and, by courtesy, of Computer Science

    Current Research and Scholarly Interests We focus on understanding the effects of genome variation on cellular phenotypes and cellular modeling of disease through genomic approaches such as next generation RNA sequencing in combination with developing and utilizing state-of-the-art bioinformatics and statistical genetics approaches. See our website at

  • Thomas Montine

    Thomas Montine

    Stanford Medicine Pathology Professor

    Bio Dr. Montine received his education at Columbia University (BA in Chemistry), the University of Rochester (PhD in Pharmacology), and McGill University (MD and CM). His postgraduate medical training was at Duke University, and he was junior faculty at Vanderbilt University where he was awarded the Thorne Professorship in Pathology. In 2002, Dr. Montine was appointed as the Nancy and Buster Alvord Endowed Professor in Neuropathology and Director of the Division of Neuropathology at the University of Washington. In 2010, Dr. Montine was appointed Chair of the Department of Pathology at the University of Washington, and in 2012 he became Director of the University of Washington Alzheimer’s Disease Research Center. In 2016, Dr. Montine was appointed Chair of the Department of Pathology at Stanford University.

    Dr. Montine is the founding Director of the Pacific Udall Center, one of 9 NINDS-funded Morris K. Udall Centers of Excellence for Parkinson’s Disease Research. Our center performs basic, translational, and clinical research focused on cognitive impairment in Parkinson’s disease. The Pacific Udall Center emphasizes a vision for precision health that comprises functional genomics, development of surveillance tools for pre-clinical detection, and discovery of molecularly tailored therapies.

    Dr. Montine is among the top recipients of NIH funding for all Department of Pathology faculty in the United States. He was the 2015 President of the American Association of Neuropathologists, and led or co-led recent NIH initiatives to revise diagnostic guidelines for Alzheimer’s disease (NIA), develop research priorities for the National Alzheimer’s Plan (NINDS & NIA), and develop research priorities for Parkinson’s Disease (NINDS).

    The focus of the Montine Laboratory is on the structural and molecular bases of cognitive impairment. Our goal is to define key pathogenic steps and thereby identify new therapeutic targets. The Montine Laboratory addresses these prevalent, unmet medical needs through a combination of neuropathology, biomarker development and application early in the course of disease, and experimental studies that test hypotheses concerning specific mechanisms of neuron injury and approaches to neuroprotection. PubMed lists 511 publications for Dr. Montine. In May 2016, Google Scholar calculates Dr. Montine’s citations as > 25,500 and his H-Index as 83.